Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Kalvista Pharmaceuticals Inc (KALV)

Kalvista Pharmaceuticals Inc (KALV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 493,178
  • Shares Outstanding, K 42,188
  • Annual Sales, $ 0 K
  • Annual Income, $ -92,910 K
  • 60-Month Beta 0.92
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.65
Trade KALV with:

Options Overview Details

View History
  • Implied Volatility 74.68% ( +35.32%)
  • Historical Volatility 40.65%
  • IV Percentile 12%
  • IV Rank 14.33%
  • IV High 285.82% on 02/01/24
  • IV Low 39.36% on 05/21/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 12
  • Volume Avg (30-Day) 51
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 1,920
  • Open Int (30-Day) 2,327

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 04/30/24
See More
  • Average Estimate -0.70
  • Number of Estimates 4
  • High Estimate -0.55
  • Low Estimate -0.84
  • Prior Year -0.77
  • Growth Rate Est. (year over year) +9.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.10 +15.69%
on 04/25/24
12.92 -9.52%
on 05/15/24
+0.25 (+2.19%)
since 04/22/24
3-Month
10.10 +15.69%
on 04/25/24
14.80 -21.01%
on 02/27/24
-0.89 (-7.07%)
since 02/22/24
52-Week
7.21 +62.14%
on 11/13/23
16.88 -30.75%
on 02/01/24
+1.12 (+10.60%)
since 05/22/23

Most Recent Stories

More News
U.S. Inflation News Due out Next Week

Monday U.S. Featured Earnings Oracle Corporation (NYSE:ORCL) (Q1) Reported EPS of 90 cents ...

FLOW.TO : 0.1900 (unch)
GRA.TO : 2.41 (+0.42%)
CXI.TO : 26.60 (unch)
ORCL : 124.60 (-0.02%)
CASY : 337.08 (+0.27%)
INNV : 4.55 (+0.44%)
EPM : 5.46 (-1.27%)
TSP : 0.2500 (-5.66%)
CBRL : 46.63 (-0.55%)
REVG : 26.85 (-1.03%)
IBEX : 15.44 (-0.19%)
ADBE : 483.93 (+0.43%)
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced...

KALV : 11.69 (+0.69%)
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate...

KALV : 11.69 (+0.69%)
KalVista Pharmaceuticals to Present Data at the 13th C1-inhibitor Deficiency & Angioedema Workshop

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced...

KALV : 11.69 (+0.69%)
Here's Why You Should Invest in Larimar (LRMR) Stock Now

Here we discuss some reasons why investing in Larimar Therapeutics (LRMR) stock now is a good idea.

RETA : 172.36 (+0.02%)
KALV : 11.69 (+0.69%)
LRMR : 7.90 (+0.13%)
SRZN : 10.55 (+8.65%)
Here's Why You Can Add KalVista (KALV) Stock to Your Portfolio

Here we discuss some reasons why investing in KalVista Pharmaceuticals (KALV) stock now is a good idea.

NKTR : 1.7500 (+2.94%)
KALV : 11.69 (+0.69%)
LRMR : 7.90 (+0.13%)
SRZN : 10.55 (+8.65%)
KalVista Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced...

KALV : 11.69 (+0.69%)
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics

Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics are part of the Zacks Industry Outlook article.

NKTR : 1.7500 (+2.94%)
CPRX : 16.14 (-2.36%)
KALV : 11.69 (+0.69%)
JNCE : 1.8800 (-2.59%)
LRMR : 7.90 (+0.13%)
5 Stocks to Buy as the Drug Industry Rebounds in 2023

Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. CPRX, KALV, LRMR, NKTR, JNCE may prove to be good additions to one's portfolio.

CPRX : 16.14 (-2.36%)
NKTR : 1.7500 (+2.94%)
KALV : 11.69 (+0.69%)
JNCE : 1.8800 (-2.59%)
LRMR : 7.90 (+0.13%)
Wall Street Analysts Think KalVista Pharmaceuticals, Inc. (KALV) Could Surge 145.98%: Read This Before Placing a Bet

The consensus price target hints at a 146% upside potential for KalVista Pharmaceuticals, Inc. (KALV). While empirical research shows that this sought-after metric is hardly effective, an upward trend...

KALV : 11.69 (+0.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which...

See More

Key Turning Points

3rd Resistance Point 12.27
2nd Resistance Point 12.06
1st Resistance Point 11.88
Last Price 11.69
1st Support Level 11.49
2nd Support Level 11.28
3rd Support Level 11.10

See More

52-Week High 16.88
Fibonacci 61.8% 13.19
Fibonacci 50% 12.05
Last Price 11.69
Fibonacci 38.2% 10.90
52-Week Low 7.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar